Ventrus Biosciences, Inc Report issue

For profit Phase 1 Phase 3
Founded: New York NY United States (2005)
Status: Acquired by Assembly Biosciences (2014)

Organization Overview

First Clinical Trial
2005
NCT01483833
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (2)

diltiazem (cardizem) (5 trials)

iferanserin (2 trials)

Drugs in Phase 1 Trials (3)

clarithromycin (biaxin) (1 trial)

sodium chloride (2 trials)

sodium monododecyl sulfate (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fissure in Ano (Phase 3)

Hemorrhoids (Phase 3)

Hypersensitivity (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 5